MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System

LEXINGTON, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/AbbVie?src=hash" target="_blank"gt;#AbbVielt;/agt;–MC10,
Inc., a healthcare technology company specializing in wearable
digital health sensors, and AbbVie
(NYSE: ABBV), a research-based global biopharmaceutical company,
announced today that the companies are working together on clinical
trials designed to explore a range of outcome measures in patients with
multiple sclerosis (MS) using the BioStamp nPoint^® system.

This innovative, patient-focused endeavor aims to explore the use of
data from the nPoint® System in order to provide unique insights into MS
clinical studies. “We are excited to work with a world leader in CNS
therapies and look forward to exploring novel data and metrics that help
to advance clinical development” commented Dr Arthur Combs, Chief
Medical Officer of MC10.

The 510(k) cleared BioStamp nPoint System was developed for use in
clinical trials and other applications for the continuous collection of
physiological data and is optimized for both in-home and in-clinic use.
The system reports vital signs, activity and postural classifications
and a suite of sleep metrics. The BioStamp nPoint System is in use today
by numerous pharmaceutical companies and in academic research across
several therapeutic areas.

“We are excited to explore the BioStamp nPoint System’s ability to
unobtrusively collect clinically relevant data continuously from
subjects in more natural settings. This technology has the potential to
improve the quality of data we collect and at the same time reduce the
burden on study participants,” commented Dr. Michael Gold, Vice
President, Development Neurosciences, of AbbVie.

About MC10
MC10 is a privately held company, backed by a
strong syndicate of financial and strategic investors, that is improving
human health through digital healthcare solutions. The company combines
its proprietary ultra-thin, flexible body-worn sensors with advanced
analytics to unlock health insights from physiological data. MC10 is
headquartered in Lexington, MA. Visit MC10 online at https://www.mc10inc.com.

MC10®, BioStamp nPoint®, and the MC10 logo are registered marks owned by
MC10, Inc.

Contacts

MC10, Inc.
Katie Nolan
[email protected]